RT @Janetbirdope: #SLE responses with #anifrolimumab separate vs standard of care+placebo& LLDAS at 12 weeks-predict
Tweet Content
#SLE responses with #anifrolimumab separate vs standard of care+placebo& LLDAS at 12 weeks-predictor was high Type I IFN (younger, ⬆️disease activity) but diff sig for response w #belimumab. At bedside diff to tell pts with various signatures apart. #EULAR2022 @RheumNow Dorner https://t.co/98Sb3MIEps
Show on Archive Page
On
Display in Search Results
On
PDQ
Off